Clinical and immimological effects of granulocyte-macrophage colony-stimulating factor coadministered with interleukin 2: A phase IB study

Clinical Cancer Research

Volumn 2, Issue 2, 1996, Pages 319-330

  Schiller, Joan H ^a   Hank, Jacquelyn A ^a   Khorsand, Masoud ^a   Storer, Barry ^a   Borchert, Agnes ^a   Huseby Moore, Karen ^a   Burns, Dan ^a   Wesly, Osvaldo ^a   Albertini, Mark R ^a   Wilding, George ^a   Sondel, Paul M ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA DR ANTIGEN; INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 2;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; EOSINOPHILIA; FEMALE; HEART ARRHYTHMIA; HUMAN; HYPOTENSION; LEUKOCYTOSIS; MALE; NEPHROTOXICITY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA;

ADULT; AGED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD56; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HLA-DR ANTIGENS; HUMANS; INTERLEUKIN-2; KILLER CELLS, LYMPHOKINE-ACTIVATED; MALE; MIDDLE AGED; NEOPLASMS; RECEPTORS, IGG; RECEPTORS, INTERLEUKIN-2;

EID: 0029916896     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Borden, E , and Sondel, P. Lymphokines and cytokines as cancer treatment, immunotherapy realized. Cancer (Phila.), 65: 800-814, 1990.
2. Rosenberg, S. New approaches to the immunotherapy of cancer using interleukin-2. Ann. Intern. Med , 108: 853-864, 1988.
3. Whittington, R., and Faulds, D. Interleukin-2, a review of its pharmacologic properties and therapeutic use in patients with cancer. Drugs, 46: 446-514, 1993.
4. Anderson, P. M., and Sorenson, M. A. Effects of route and formulation on clinical pharmacokinetics of interleukin-2. Clin. Pharmacokinet., 27: 19-31, 1994
5. Rosenberg, S. A., Yang, J C , Topalian, S. L., Schwartzentruber, D. J., Weber, J. S., Parkinson, D. R., Seipp, C. A., Einhorn, J. H., and White, D. E. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high dose bolus interleukin-2. JAMA, 271: 907-913, 1994.
6. Cheever, M., Greenberg, P., Fefer, A , and Gillis, S. Augmentation of the antitumor therapeutic efficacy of long-term cultured T lymphocytes by in vitro administration of purified interleukin-2 J. Exp. Med., 155: 968-980, 1982.
7. Hank, J., Kohler, P., Hillman, G , Rosenthal, N., Moore, K., Storer, B., Minkoff, D., Bradshaw, J., Bechhofer, R., and Sondel, P. In vivo induction of the lymphokine-activated killer phenomenon: interleukin 2-dependent human non-major histocompatibility complex-restricted cytotoxicity generated in vivo during administration of human recombinant interleukin 2. Cancer Res., 48: 1965-1971, 1988.
8. Sosman, J. A., Kohler, P. C., Hank, J., Moore, K. H., Bechhofer, R., Storer, B., and Sondel, P. M. Repetitive weekly cycles of interleukin-2. II. Clinical and immunological effects of dose, schedule, and addition of indomethacin. J. Natl. Cancer Inst., 80: 1451-1461, 1988.
9. Hank, J., Robinson, R., Surfus, J., Mueller, B., Reisfeld, R., Cheung, N., and Sondel, P. Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2. Cancer Res., 50: 5234-5239, 1990.
10. Smith, K., Lachman, L., Oppenheim, J., and Favata, M. The functional relationship of the interleukins. J. Exp. Med., 154: 1551-1556, 1980.
11. Rosenberg, S. A. The immunotherapy and gene therapy of cancer. J. Clin. Oncol., 10: 180-199, 1992.
12. Schiller, J., Hank, J , Storer, B., Borchert, A., Moore, K., Albertini, M., Bechhofer, R., Wesley, O., Brown, R., Bastin, A., and Sondel, P. A direct comparison of immunological and clinical effects of interleukin 2 with and without interferon-α in humans. Cancer Res., 53: 1286-1292, 1993.
13. Sznol, M., Clark, J., Smith, J., Steis, R., Urba, W., Rubinstein, L., VanderMolen, L., Janik, J., Sharfman, W., Fenton, R., Creekmore, S., Kremers, R., Conlon, K., Hursey, J., Beveridge, J., and Longo, D. Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon α-2a in patients with metastatic melanoma and renal cell carcinoma. J. Natl. Cancer Inst., 84: 929-937, 1992.
14. Budd, G. T., Osgood, B., Barna, B., and Bukowski, R. M. Phase I clinical trial of interleukin 2 and α-interferon: toxicity and immunologic effects. Cancer Res., 49: 6432-6436, 1989.
15. Hank, J. A., Albertini, M., Wesly, O. H., Schiller, J. H., Borchert, A., Moore, K., Bechhofer, R., Storer, B., Gan, J., Gambacorti, C., Sosman, J., and Sondel, P. M. Clinical and immunological effects of treatment with murine anti-CD3 monoclonal antibody along with interleukin 2 in patients with cancer. Clin. Cancer Res., 1: 481-491, 1995.
16. Sosman, J. A., Weiss, G. R., Margolin, K. A., Aronson, F. R., Sznol, M., Atkins, M. B., O'Boyle, K., Fisher, R. I., Boldt, D. H., Doroshow, J., Ernest, M. L., Fisher, S. G., Mier, J., Vachino, G., and Caliendo, G. Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma, clinical and immunologic effects. J. Clin. Oncol., 11: 1496-1505, 1993.
17. Metcalf, D. The molecular biology and functions of the granulocyte-macrophage colony stimulating factors. Blood 67: 35-43, 1987.
18. Munn, D., Garnick, M., and Cheung, N. Effects of parenteral recombinant human macrophage colony-stimulating factor on monocyte number, phenotype, and antitumor cytotoxicity in nonhuman primates. Blood, 75. 2042-2048, 1990.
19. Munn, D., and Cheung, N-K. Phagocytosis of rumor cells by human monocytes cultured in recombinant macrophage colony stimulating factor. J. Exp. Med., 172: 231-237, 1990.
20. Munn, D., and Cheung, N. Antibody-dependent antitumor cytotoxicity by human monocytes cultured with recombinant macrophage colony-stimulating factor. J. Exp. Med., 170: 511-526, 1989.
21. Grabstein, K., Urdal, D., Tushinski, R., Mochizuki, D., Price, V., Cantrell, M., Gillis, S., and Conlon, P. Induction of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor. Science (Washington DC), 232: 506-508, 1986.
22. Thomassen, M., Ahmad, M., Barna, B., Antal, J., Wiedmann, H., Meeker, D , Klein, J., Bauer, L., Gibson, V., Andresen, S., and Bukowski, R. Induction of cytokine messenger RNA and secretion in alveolar macrophages and blood monocytes from patients with lung cancer receiving granulocyte-macrophage colony-stimulating factor. Cancer Res., 51: 857-862, 1991.
23. Morrissey, P., Bressler, L., Charrier, K., and Alpert, A. Response of resident murine peritoneal macrophages to in vivo administration of granulocyte-macrophage colony-stimulating factor. J. Immunol., 140: 1910-1915, 1988.
24. Charak, B., Agah, R., and Mazumder, A. Granulocyte-macrophage colony-stimulating factor-induced antibody-dependent cellular cytotoxicity in bone marrow macrophages: application in bone marrow transplantation. Blood, 81: 3474-3479, 1993.
25. Sanda, M., Bolton, E., Mulé, J. J., and Rosenberg, S. A. In vivo administration of recombinant macrophage colony-stimulating factor induces macrophage-mediated antibody-dependent cytotoxicity of tumor cells. J. Immunother., 12: 132-137, 1992.
26. Chachoua, A., Oratz, R., Hoogmoed, R., Caron, D., Peace, D., Liebes, L., Blum, R., and Vilcek, J. Monocyte activation following systemic administration of granulocyte-macrophage colony-stimulating factor. J. Imunother., 15: 217-224, 1994.
27. Kleinerman, E., Knowles, R., Lachman, L., and Gutterman, J. Effect of recombinant granulocyte/macrophage colony-stimulating factor on human monocyte activity in vitro and following intravenous administration. Cancer Res., 48: 2604-2609, 1988.
28. Weiner, L., Li, W., Holmes, M., Catalono, R., Dovnarsky, M., Padavic, K., and Alpaugh, R. Phase I trial of recombinant macrophage colony-stimulating factor and recombinant γ interferon: toxicity, monocytosis, and clinical effects. Cancer Res., 54: 4084-4090, 1994.
29. Gearing, A. J. H., and Thorpe, R. The international standard for human interleukin-2: calibration by international collaborative study. J. Immunol. Methods. 114: 3-9, 1988.
30. Weil-Hillman, G., Fisch, P., Prieve, A. F., Sosman, J. A., Hank, J. A., and Sondel, P. M. Lymphokine-activated killer activity induced by in vivo interleukin 2 therapy: predominant role for lymphocytes with increased expression of CD2 and Leu19 antigens but negative expression of CD16 antigens. Cancer Res., 49: 3680-3688, 1989.
31. Bock, S., Cameron, R., Kragel, P., Mule, J., and Rosenberg, S. Biological and antitumor effects of recombinant human macrophage colony-stimulating factor in mice. Cancer Res., 51: 2649-2654, 1991.
32. Walsh, P., Dorner, A., Duke, R. C., Su, L. J., and Glode, L. M. Macrophage colony-stimulating factor complementary DNA: a candidate for gene therapy in metastatic melanoma. J. Natl. Cancer Inst., 87: 809-816, 1995.
33. Lee, S. S., Eisenlohr, L. C., McCue, P. A., Mastrangelo, M. J., Fink, E., and Lattime, E. C. In vivo gene therapy of murine tumors using recombinant vaccinia virus encoding GM-CSF. Proc. Am. Assoc. Cancer Res., 36: 248, 1995.
34. Dranoff, G , Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V., Hamada, H , Pardoll, D., and Mulligan, R. C. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony stimulating factor stimulates potent, specific, and long-lasting antitumor immunity. Proc. Natl. Acad. Sci. USA, 90: 3539-3543, 1993.
35. Cole, D., Sanda, M., Yang, J., Schwartzentruber, D., Weber, J., Ettinghausen, S., Pockaj, B., Kim, H., Levin, R., Pogrebniak, H., Balkissoon, J., Fenton, R., DeBarge, L., Kaye, J., Rosenberg, S., and Parkinson, D. Phase I trial of recombinant human macrophage colony-stimulating factor administered by continuous intravenous infusion in patients with metastatic cancer. J. Natl. Cancer Inst., 86: 39-45, 1994.
36. Sanda, M., Yang, J., Topalian, S., Groves, E., Childs, A., Belfort, R., Jr , de Smet, M., Schwartzentruber, D., White, D., Lotze, M., and Rosenberg, S. Intravenous administration of recombinant human macrophage colony-stimulating factor to patients with metastatic cancer: a phase I study. J. Clin. Oncol., 10: 1643-1649, 1992.
37. Zamkoff, K., Hudson, J., Groves, E., Childs, A., Konrad, M., and Rudolph, A. A phase I trial of recombinant human macrophage colony-stimulating factor by rapid intravenous infusion in patients with refractory malignancy. J. Immunother., 11: 103-110, 1992.
38. Ragnhammar, P., Magnusson, I., Masucci, G., and Mellstedt, H. The therapeutic use of the unconjugated monoclonal antibodies (MAb) 17-1A in combination with GM-CSF in the treatment of colorectal carcinoma (CRC). Med. Oncol. Tumor Pharmacother., 10: 61-70, 1993.
39. Kerst, J. M., de Haas, M., van der Schoot, C. E., Slaper-Cortenbach, I. C , Kleijer, M., von dem Borne, A. E., and van Oers, W. H. Recombinant granulocyte colony-stimulating factor administration to healthy volunteers: induction of immunophenotypically and functionally altered neutrophils via an effect on myeloid progenitor cells. Blood. 82: 3265-3272, 1993.
40. Valerius, T., Repp, R., deWit, T. P., Berthold, S., Platzer, E., Kalden, J. R., Gramatzki, M., and van de Winkel, J. G. Involvement of the high-affinity receptor for IgG (Fc gamma RI; CD64) in enhanced tumor cell cytotoxicity of neutrophils during granulocyte colony-stimulating factor therapy. Blood. 82: 931-939, 1993
41. Ho, A. D., Haas, R., Wulf, G., Knauf, W., Ehrhardt, R., Heilig, B., Körbling, M., Schulz, G., and Hunstein, W. Activation of lymphocytes induced by recombinant human granulocyte-macrophage colony-stimulating factor in patients with malignant lymphoma. Blood, 75: 203-212, 1990.
42. Santoli, D., Clark, S. C., Kreider, B. L., Maslin, P. A., and Rovera G. Amplification of IL-2-driven T cell proliferation by recombinant human IL-3 and granulocyte-macrophage colony-stimulating factor. J. Immunol., 141: 519-526, 1988
43. Stewart-Akers, A. M., Cairns, J. S., Tweardy, D. J., and McCarthy, S. A. Effect of granulocyte-macrophage colony-stimulating factor on lymphokine-activated killer cell induction. Blood, 81: 2671-2678, 1993.
44. Karp, B., Yang, J., and Khorsand, M. Multiple cerebral lesions complicating therapy with interleukin-2 (Abstract). Neurology, 45 (Suppl. 4): A400, 1995.
45. Moore, P. M., Harley, J. B., and Fauci, A. S. Neurologic dysfunction in the idiopathic hypereosinophilic syndrome. Ann. Intern. Med., 102: 109-114, 1985.
46. Gardner-Thorpe, G., Harriman, D. G., Parsons, M., and Rudge, P. Loffler's eosinophilic endocarditis with Balint's syndrome. Q. J. Med. 40: 249-260, 1971.
47. Slungaard, A., Vercellotti, G. M., Tran, T., Gleich, G. J., and Key, N. S. Eosinophil cationic granule proteins impair thrombomodulin function A potential mechanism for thromboembolism in hypereosinophilic heart disease. J. Clin. Invest., 91: 1721-1730, 1993.
48. Dittman, W. A., and Majerus, P. W. Structure and function of thrombomodulin: a natural anticoagulant. Blood 75: 329-336, 1990.
49. Esmon, C. T. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J. Biol. Chem., 264: 4743-4746, 1989.
50. Maruyama, I., Bell, C. E., and Majerus, P. W. Thrombomodulin is found on endothelium of arteries, veins, capillaries, and lymphatics and syncytiotrophoblast of human placenta. J. Cell Biol. 101: 363-371, 1985.